EMA publishes single Q&A document for biosimilars submitted via centralised procedure
This article was originally published in SRA
Executive Summary
The European Medicines Agency has published a document designed to answer regulatory and procedural questions from companies using the centralised procedure to gain approval for their biosimilars1,2.